BioSpace News Archive

Primmune Therapeutics today announced that they will present interim Phase 1 clinical data for PRTX007, a novel, orally administered, small molecule toll-like receptor 7 (TLR7) specific agonist, at the 2022 American Association Meeting.

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced the launch of the Accelerate Arc system, comprised of the Arc Module and BC Kit, an automated path to rapid and accurate microbial identification for positive blood cultures.

miR Scientific, and Leonie Hill Capital, announced today the signing of a collaboration agreement to partner in the commercial launch of the award-winning miR Sentinel™ Prostate Cancer Test in Singapore and Southeast Asia.

BigHat Biosciences, Inc., a biotechnology company developing safer, more effective next-generation antibody therapies for patients using machine learning and synthetic biology, today announced the acquisition of Frugi Biotechnology, a biotechnology company developing cost-effective and high-quality cell-free protein synthesis (CFPS) technology.

Alphatec Holdings, Inc. announced that Pat Miles, Chairman and Chief Executive Officer, and Todd Koning, Chief Financial Officer, will present at the 21st Annual Needham Virtual Healthcare Conference on April 11, 2022, at 11:45am ET.

Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that the diagnostic 64Cu SAR-bisPSMA trial for patients with prostate cancer is open for recruitment.

Therapeutic Solutions International announced today its Board of Directors has selected Biorasi as the contract research organization (CRO) to run its Pivotal FDA Registration Clinical Trial assessing efficacy of its JadiCell™ Adult Stem Cell Product in patients with advanced COVID-19.

FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that FUJIFILM Irvine Scientific, Inc., a world leader in the development and manufacture of serum-free and chemically defined cell culture media for life science research, bioproduction, and cell therapy manufacturing, completed the acquisition of Shenandoah Biotechnology, Inc.

Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, announced that the Company has entered into a second collaboration with Richard K. Porter, Ph.D., of the School of Biochemistry & Immunology at Trinity College Dublin, Ireland.

The Lung Cancer Research Foundation (LCRF) and ALK Positive Inc. (ALK Positive) announce a research partnership to fund ALK-positive related lung cancer projects.